Le igg in terapia immunodulante utili in covid-19?
Barra laterale dell'articolo
Contenuto principale dell'articolo
Abstract
Allo stato attuale delle conoscenze sull’uso di immunoglobuline iperimmuni e IVIgG in corso di COVID-19, non si possono ancora trarre linee di indirizzo generale.
Resta importante identificare le circostanze cliniche che rendono le opzioni realmente utilizzabili a vantaggio del malato.
Se il trattamento con anticorpi derivati da plasma di soggetti immuni post-COVID-19 trova comunque un suo specifico razionale terapeutico nell’ambito della stessa storia naturale della malattia, le IVIgG ad alte dosi dovrebbero essere impiegate in protocolli definiti con adeguata impostazione esecutiva per la ricerca di un efficace rapporto costo/beneficio, in particolar modo
considerando studi collaborativi multicentrici, che utilizzino parametri di valutazione condivisi e confrontabili.
Downloads
Dettagli dell'articolo
Questo lavoro è fornito con la licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 4.0 Internazionale.
Riferimenti bibliografici
-De Martino M, Rossi ME, Vierucci A. Gli anticorpi. Biologia e uso clinico. Annali Sclavo n. 1 (collana monografica). Siena: Ed. Sclavo SpA 1984.
-Cohn EJ, Mc Meekin TL, Oncley JL et al. Preparation and properties of serum and plasma proteins. V. Size and charge of proteins separating out upon equilibration across membranes with ammonium sulphate, solutions of controlled pH, ionic strength and temperature J Am Chem Soc 1940; 62: 3386 –
-Oncley JL, Melin M, Richert DA, et al. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen, and b1 lipoprotein into subfractions of human plasma J Am Chem Soc 1949; 71: 541 –
-Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nature Rev Drug Discovery 2003; 2:52.
-Schroeder HW, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010; 125:41-52.
-Abe Y, Gor J, Bracewell DG, et al. Masking of the Fc region in human IgG4 by constrained X-ray scattering modelling: implications for antibody function and therapy. Biochem J 2010; 432:101-111.
-Imbach P, Barandun S, d’Apuzzo V, et al. Highdose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1:1228-31.
-Nimmerjahn F, Ravetch JV. The anti-inflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 2007; 204:11-15.
-Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Ann Rev Immunol 2008; 26:513-533.
-Martin TD. IGIV: contents, properties, and methods of industrial production – evolving closer to a more physiologic product. Int Immunopharmacol 2006; 6:517–22.
-Luzi G IVIG:storia di un’idea GSE srl-Edizioni, 2005
-Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291:484–6.
- Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Siberil S, et al. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis form B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmunity 2011; 36:9–15.
- Siragam V, Brinc D, Crow AR, Song S, Freedman J, Lazarus AH. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest 2005; 11:155–60.
-Luzi G Immunomodulanti naturali: le immunoglobuline IgG dal laboratorio alla clinica Rivista di Immunologia e Allergologia Pediatrica 2011; 6: 27-35.
-Hu, B., Guo, H., Zhou, P. et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol (2020). [6 Ottobre 2020] https://doi.org/10.1038/s41579-020-00459
- Stadnytskyi, V., Bax, C. E., Bax, A. & Anfinrud, P. The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission. Proc. Natl Acad. Sci. USA 117, 11875–11877 (2020).
- Meselson, M. Droplets and aerosols in the transmission of SARS-CoV-2. N. Engl. J. Med. 382, 2063 (2020).
- van Doremalen, N. et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N. Engl. J. Med. 2020; 382: 1564–1567.
- Wu, Z. & McGoogan, J. M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239–1242.
-Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507–513.
- BS Kamps, C. Hoffmann – COVID Reference / ITA 2020.4 Ed Steinhauser-Verlag 6 see. 2020
-Perotti C, Baldanti F, Bruno R. et al Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial Haematologica Early view Jul 23, 2020 https://doi.org/10.3324/haematol.2020.261784 24]- Hamed MA An overview on COVID-19: reality and expectation Hamed Bulletin of the National Research Centre (2020) 44:86 https://doi.org/10.1186/s42269-020-00341-9
- Chai KL, Valk SJ. Piechotta V et al.Convalescent plasma or hyperimmune immunoglobulin for people with covid19: a living systematic reviewCochrane Systematic Review - Intervention Version published: 12 October 2020 https://doi.org/10.1002/14651858.CD013600.pub3
- NHS [Royal Cornwall Hospitals] -Use of Human Normal Immunoglobulin (IVIg/SCIg) Clinical Guideline V3.0 January 2019
- 28 June 2018 EMA/CHMP/BPWP/94033/2007 rev. 3 Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg)
- Linee guida sull’uso delle soluzioni delle immunoglobuline e di albumina umana Tradotte e adattate da: NHS – Scotland Clinical Guidelines for Immunoglobuline use Marzo 2012
-Ruklanthi de Alwisa,b , Shiwei Chena , Esther S. Gana , Eng Eong Ooia, Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development EBioMedicine 55 (2020) 102768
-NIH/COVID-19 Treatment Guidelines Downloaded from https://www.covid19treatmentguidelines.nih.gov/ on 11/21/2020
-Xie Y, Cao S, Dong H et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19 Jour of Infection/Letter to the Editor 2020; 81:318-356 / https://doi.org/10.1016/j.jinf.2020.03.044 [pag. 340-343].
-Sakoulas G, Geriak M, Kullar R et al Intravenous immunoglobulins (IVIG) significantly reduces respiratory morbidity in COVID-19 pneumonia: a prospective randomized trial medRxiv preprint (version posted July 25,2020).
-Scoppetta C, Di Gennaro G, polverino F – Edit. – High dose intravenous immunoglobulins as a therapeutic option for COVID-19 pts Eur Rev Med Pharmacol 2020; 24:5178-5179
-Zhao H, Shen D, Liu J et al Guillain-Barrè sundrome associate with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol 2020; 19:383-384
-Nguyen A, Habiballah SB, Platt C et al. Immunoglobulins in the treatment of CoViD-19 infection: proceed with caution Clinical Immunology 216 (2020) 108459
-Cao W, Liu X, Bai T, 3 et al. High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients with Coronavirus Disease 2019 Open Forum Infectious Diseases - https://academic.oup.com/ofid/article-abstract/7/3/ofaa102/5810740
- Reynaga E, y, Carrillo J, y, Jose Ramon Santos J et al. -Letter to the Editor - Outcome of hospitalized patients with COVID-19 pneumonia treated with high-dose immunoglobulin therapy in a prospective case series Clinical Microbiology and Infection https://doi.org/10.1016/j.cmi.2020.10.010 1198-743X/© 2020